Cerus (NASDAQ:CERS) Issues Earnings Results, Meets Estimates

Cerus (NASDAQ:CERS) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01), Zacks reports. Cerus had a negative net margin of 11.19% and a negative return on equity of 37.90%.

Cerus Price Performance

Shares of CERS stock traded down $0.07 on Thursday, reaching $1.74. The company had a trading volume of 1,190,299 shares, compared to its average volume of 1,469,572. The stock has a market capitalization of $323.14 million, a PE ratio of -15.82 and a beta of 1.29. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. The business’s 50-day moving average is $1.74 and its 200 day moving average is $1.84. Cerus has a one year low of $1.38 and a one year high of $2.59.

Insider Buying and Selling

In related news, Director Eric Bjerkholt sold 20,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $1.78, for a total transaction of $35,600.00. Following the sale, the director now owns 162,133 shares of the company’s stock, valued at $288,596.74. This trade represents a 10.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 3.40% of the stock is owned by corporate insiders.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.